Clinical Trials
80 trialsNCT07082270 2026-05-15
Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma
Roswell Park Cancer Institute
Phase 1 Withdrawn
NCT07217496 2026-03-17
N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer
University of California, San Francisco
Phase 1 Withdrawn
NCT06626256 2025-12-24
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
City of Hope Medical Center
Phase 1 Withdrawn
NCT05904704 2025-11-14
Oxygen-Enhanced MRI for Generating Hypoxia Maps in Patients With Intracranial Tumors
OHSU Knight Cancer Institute
Phase NA Withdrawn
NCT05720624 2025-10-22
Pharmacodynamic Analyses of Metabolic Agents Following Brain Radiation
Mayo Clinic
Phase 1 Withdrawn
NCT04910425 2025-10-21
PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer
Northwestern University
Phase 2 Withdrawn
NCT05564416 2025-10-21
Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT05483023 2025-10-14
18-fluorofuranylnorprogesterone (FFNP) PET/MRI as a Potential Biomarker of Response to Progesterone Therapy
UNC Lineberger Comprehensive Cancer Center
Phase 2 Withdrawn
NCT06730100 2025-10-06
CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT06528210 2025-09-23
Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Withdrawn
NCT06670976 2025-08-26
Propranolol Plus Standard Radiation Therapy Before Surgery for the Treatment of Patients With Soft Tissue Sarcoma
Roswell Park Cancer Institute
Phase 1 Withdrawn
NCT05717140 2025-08-07
Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung
Mayo Clinic
Phase 1 Withdrawn
NCT06590558 2025-07-03
Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer
National Cancer Institute (NCI)
Phase 1 Withdrawn
NCT06393751 2025-06-03
Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer
National Cancer Institute (NCI)
Phase 1/2 Withdrawn
NCT05840770 2025-05-26
Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer
City of Hope Medical Center
Phase 2 Withdrawn
NCT06572631 2025-05-25
Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor
City of Hope Medical Center
Phase 1 Withdrawn
NCT05600556 2025-05-15
Virtual Reality for the Improvement of Patients Understanding of Disease and Treatment (MRgRT)
Thomas Jefferson University
Phase NA Withdrawn
NCT06390657 2025-05-11
S-C-PATHY
EBG MedAustron GmbH
Withdrawn
NCT03581500 2025-04-23
Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT06206876 2025-01-17
FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma
Roswell Park Cancer Institute
Phase 1 Withdrawn
NCT05653661 2025-01-07
Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors
Mayo Clinic
Phase 1 Withdrawn
NCT06328036 2024-12-30
Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT06575725 2024-11-21
Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer
City of Hope Medical Center
Phase 2 Withdrawn
NCT04580836 2024-10-26
MRI-Guided Radiation Therapy for the Treatment of Early-Stage Kidney Cancer, the MRI-MARK Trial
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT06427369 2024-09-27
An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer
Roswell Park Cancer Institute
Phase 1 Withdrawn
NCT04023240 2024-08-12
68-Ga-FAPI PET Imaging in Malignancy
Stanford University
Phase 2 Withdrawn
NCT06084845 2024-07-25
Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck Cancer
Eastern Cooperative Oncology Group
Phase 2 Withdrawn
NCT06398587 2024-07-19
Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma
OHSU Knight Cancer Institute
Phase 2 Withdrawn
NCT05936229 2024-07-12
Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy
Fred Hutchinson Cancer Center
Phase 1/2 Withdrawn
NCT06210750 2024-05-17
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT06400264 2024-05-06
Testing Nivolumab and BMS-986016 (Relatlimab) as Potentially Targeting Treatment in Cancers That Are LAG-3+ and Have Mismatch Repair Deficiency (MATCH - Subprotocol Z1M)
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT05807126 2024-05-02
Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations
National Cancer Institute (NCI)
Phase 1 Withdrawn
NCT05950113 2024-05-01
CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma
Jonsson Comprehensive Cancer Center
Phase 1 Withdrawn
NCT06137651 2024-04-01
Trotabresib in Combination With Vinorelbine and Radiation Therapy for the Treatment of HER2+ Breast Cancer With Central Nervous System or Leptomeningeal Metastasis
Northwestern University
Phase 1 Withdrawn
NCT05967286 2024-03-20
Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT04140513 2024-03-08
Digital PET Scan for the Prediction of Outcomes in Patients With Locally Advanced Oropharyngeal Cancer
Ohio State University Comprehensive Cancer Center
Phase NA Withdrawn
NCT05034562 2024-03-07
Gallium-68 PSMA-11 PET in Participants With Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT05111314 2023-11-07
Comparison of Hepatic Intraarterial Versus Systemic Intravenous 68Ga-PSMA PET/CT for Detection of Hepatocellular Carcinoma
Mayo Clinic
Phase EARLY_PHASE1 Withdrawn
NCT05728372 2023-10-10
64Cu-DOTA Pembrolizumab for Imaging Metastatic Solid Tumors in Patients Receiving Stereotactic Body Radiation
City of Hope Medical Center
Phase EARLY_PHASE1 Withdrawn
NCT04989283 2023-09-26
Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT05295589 2023-09-26
Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT05935774 2023-08-25
OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer
University of Washington
Phase 2 Withdrawn
NCT05677373 2023-08-18
Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma
Alliance for Clinical Trials in Oncology
Phase 1/2 Withdrawn
NCT02607423 2023-05-25
Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery
Eastern Cooperative Oncology Group
Phase 2 Withdrawn
NCT04483414 2023-05-19
68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer
University of Texas Southwestern Medical Center
Phase 2 Withdrawn
NCT04605614 2022-06-09
64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression
City of Hope Medical Center
Phase 1 Withdrawn
NCT03234309 2021-11-10
Ferumoxytol in Magnetic Resonance Imaging of Pediatric Patients With Brain Tumors
OHSU Knight Cancer Institute
Phase 2 Withdrawn
NCT02857218 2021-09-16
Ferumoxytol-Enhanced MRI in Imaging Lymph Nodes in Patients With Stage IIB-IIIC Esophageal Cancer
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Withdrawn
NCT02919332 2020-07-24
Delayed 18F-FDG PET/CT in Improving Visualization of Brain Tumors in Patients With Glioblastoma
Jonsson Comprehensive Cancer Center
Withdrawn
NCT03506802 2020-07-24
NYSCT MM
Jonsson Comprehensive Cancer Center
Phase 1 Withdrawn